Back to All

Diaceutics wins award for IPO of the year at 2020 Small Cap Awards

13 July, 2020

Dundalk/Belfast, 13 July 2020 – Diaceutics PLC, (AIM: DXRX), today announces that it has won the award for IPO of the Year at this year’s Small Cap Awards. The awards, which were virtually hosted via Zoom at the end of June, celebrate the finest in the sub-£200 million market cap quoted company sector and recognize the success of the organizations that work within the AIM and NEX exchange communities.

Since its listing on the AIM (Alternative Investment Market) of the London Stock Exchange in March 2019, Diaceutics has gone from strength to strength. Earlier this year, in its 2019 annual results, the company reported a 30% rise in revenues to £13.4M, as well as gross profit growth of 52% to £1.3M. And in June this year, Diaceutics announced that it had raised in a share placing as it prepares for an increased demand for commercial diagnostic services.

Key to this future growth will be the Q4 2020 launch of Diaceutics′ DXRX platform – the world’s first diagnostic network for precision medicine. The network will enable the industry-wide collaboration required to unlock the power of precision medicines and ensure every eligible patient gets the treatment they need, when they need it.

Following its IPO of the Year achievement, Diaceutics received a nomination in the International Star category in the European Small and Mid-Cap Awards which are due to take place in November 2020. A joint initiative by Europeanissuers, the Federation of European Securities Exchanges (FESE) and the European Commission, these awards showcase SMEs that recently went through an IPO.

Peter Keeling, Diaceutics founder and CEO, said:

Peter Keeling

Peter Keeling, CEO of Diaceutics: “We are absolutely delighted, not only with the award and nomination, but also the progress we have made over the last 18 months. The IPO has enabled us to grow, invest in our company and platform and increase our market share. Now we must build on this and further penetrate the precision testing market, and that’s where DXRX comes in. We are very excited to roll this platform out and witness the impact it has for patients across the globe.”

Other nominees in the category included Brickability Group, Essensys, Argentex Group PLC, Loungers and Pebble Group.

Full details of the awards, category recipients, previous winners and judging panels can be found here.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny